F Eichelmann1, N Rudovich2,3,4,5, A F Pfeiffer2,3,5, M B Schulze5,6, R D Giuseppe7, H Boeing8, K Aleksandrova1. 1. Nutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. 2. Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, DIfE, Nuthetal, Germany. 3. Department of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Charité University Medicine, Berlin, Germany. 4. Spital Bülach, Bülach, Switzerland. 5. German Center of Diabetes Research (DZD), Germany. 6. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. 7. Institute of Epidemiology, Christian-Albrechts University Kiel, Kiel, Germany. 8. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.
Abstract
BACKGROUND: Adipokines could pose a link between adiposity, systemic inflammation and metabolic disease risk. However, it is unclear whether representative biomarkers are methodologically suitable for use in human obesity research. METHODS: We assessed the intra-individual reproducibility of selected adipokines in a sample of 207, apparently healthy, participants with available biosample collections over a 4-month period. Concentrations of the following adipokines were measured at each sampling time point: fatty-acid binding protein-4 (FABP-4), lipocalin-2, monocyte chemoattractant protein 1 (MCP-1), procalcitonin, progranulin, vaspin and visfatin/Nampt. We calculated intraclass correlation coefficients (ICC) and examined Bland-Altman plots. RESULTS: The analyses suggested an overall good to excellent biomarker reproducibility over 4 months: FABP-4: ICC=0.73 (95% confidence interval: 0.65, 0.78), lipocalin-2: 0.64 (0.55, 0.71), MCP-1: 0.85 (0.81; 0.89), procalcitonin: 0.78 (0.72, 0.83), progranulin: 0.59 (0.50, 0.68) and vaspin: 0.86 (0.82, 0.89). A good agreement of the repeated measurements was further supported by the Bland-Altman plots. No substantial differences in biomarker performance according to adiposity status could be observed. Reliability of visfatin/Nampt could not be assessed due to a high number of measurements below the lower limit of detection. CONCLUSION: Results suggest that single measurements of the evaluated adipokines could be used in population-based studies aimed to assess links between obesity, inflammation and metabolic diseases.
BACKGROUND: Adipokines could pose a link between adiposity, systemic inflammation and metabolic disease risk. However, it is unclear whether representative biomarkers are methodologically suitable for use in humanobesity research. METHODS: We assessed the intra-individual reproducibility of selected adipokines in a sample of 207, apparently healthy, participants with available biosample collections over a 4-month period. Concentrations of the following adipokines were measured at each sampling time point: fatty-acid binding protein-4 (FABP-4), lipocalin-2, monocyte chemoattractant protein 1 (MCP-1), procalcitonin, progranulin, vaspin and visfatin/Nampt. We calculated intraclass correlation coefficients (ICC) and examined Bland-Altman plots. RESULTS: The analyses suggested an overall good to excellent biomarker reproducibility over 4 months: FABP-4: ICC=0.73 (95% confidence interval: 0.65, 0.78), lipocalin-2: 0.64 (0.55, 0.71), MCP-1: 0.85 (0.81; 0.89), procalcitonin: 0.78 (0.72, 0.83), progranulin: 0.59 (0.50, 0.68) and vaspin: 0.86 (0.82, 0.89). A good agreement of the repeated measurements was further supported by the Bland-Altman plots. No substantial differences in biomarker performance according to adiposity status could be observed. Reliability of visfatin/Nampt could not be assessed due to a high number of measurements below the lower limit of detection. CONCLUSION: Results suggest that single measurements of the evaluated adipokines could be used in population-based studies aimed to assess links between obesity, inflammation and metabolic diseases.
Authors: Ali Abbasi; Eva Corpeleijn; Douwe Postmus; Ron T Gansevoort; Paul E de Jong; Rijk O B Gans; Joachim Struck; Hans L Hillege; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker Journal: J Clin Endocrinol Metab Date: 2010-06-09 Impact factor: 5.958
Authors: Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: Aimin Xu; Annette W K Tso; Bernard M Y Cheung; Yu Wang; Nelson M S Wat; Carol H Y Fong; Dennis C Y Yeung; Edward D Janus; Pak C Sham; Karen S L Lam Journal: Circulation Date: 2007-03-27 Impact factor: 29.690
Authors: Tricia Peters; Soren Brage; Kate Westgate; Paul W Franks; Anna Gradmark; Maria Jose Tormo Diaz; Jose Maria Huerta; Benedetta Bendinelli; Mattheaus Vigl; Heiner Boeing; Wanda Wendel-Vos; Annemieke Spijkerman; Kristin Benjaminsen-Borch; Elisavet Valanou; Blandine de Lauzon Guillain; Françoise Clavel-Chapelon; Stephen Sharp; Nicola Kerrison; Claudia Langenberg; Larraitz Arriola; Aurelio Barricarte; Carlos Gonzales; Sara Grioni; Rudolf Kaaks; Timothy Key; Kay Tee Khaw; Anne May; Peter Nilsson; Teresa Norat; Kim Overvad; Domenico Palli; Salvatore Panico; Jose Ramón Quirós; Fulvio Ricceri; Maria-Jose Sanchez; Nadia Slimani; Anne Tjonneland; Rosario Tumino; Edith Feskins; Elio Riboli; Ulf Ekelund; Nick Wareham Journal: Eur J Epidemiol Date: 2011-11-17 Impact factor: 8.082
Authors: Matthew Schenk; Fabian Eichelmann; Matthias B Schulze; Natalia Rudovich; Andreas F Pfeiffer; Romina di Giuseppe; Heiner Boeing; Krasimira Aleksandrova Journal: Biomark Med Date: 2019-06-03 Impact factor: 2.851
Authors: Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo Journal: Int J Mol Sci Date: 2017-08-15 Impact factor: 5.923
Authors: Jan Bieńkiewicz; Hanna Romanowicz; Miłosz Wilczyński; Grzegorz Jabłoński; Anna Stepowicz; Anna Obłękowska; Andrzej Malinowski; Beata Smolarz Journal: BMC Cancer Date: 2021-08-16 Impact factor: 4.430